Saturday 17 October 2026
Export PROCF’s income statement to Excel — free account
Sofgen Pharma S.A
PROCF Healthcare Drug Manufacturers Specialty & Generic
0.03
0.00
0.00%
Follow PROCF
| Dec '23 | Sep '23 | Jun '23 | Mar '23 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
6 | 4 | 4 | — |
+8 more TTM periods Free account |
| (213.06%) | 327.75% | 4,898.25% | (363.02%) | ||
| 8.82% | 9.44% | 12.52% | 5.69% | ||
ROIC |
15.21% | 0.71% | 1.57% | 2.47% | |
Return on Tangible Assets |
(60.27%) | 23.77% | 41.94% | 22.32% | |
Average Days of Receivables |
107.54 | 128.17 | 124.79 | 105.72 | |
Free Cash Flow per Share |
0.74 | 0.32 | (0.09) | (0.21) | |
Free Cash Flow |
74.84 | 31.99 | (9.43) | (20.95) | |
Capital Expenditures |
(32.79) | (32.44) | (32.22) | (33.28) | |
| Other line items | |||||
Cash ROIC |
21.77% | 8.93% | (2.74%) | (6.62%) | |
Accounts Receivable Turnover |
3.66 | 2.99 | 3.11 | 3.53 | |
Accounts Payable Turnover |
0.00 | 1.99 | 2.00 | 2.23 | |
Inventory Turnover |
1.84 | 1.85 | 1.74 | 1.70 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
200.06 | 194.98 | 213.68 | 215.84 | |
Tax Rate |
(0.12) | (0.27) | (0.26) | (0.24) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
45.63% | 47.22% | 46.91% | 48.73% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
— | 0.07 | 0.17 | 0.27 | |
Operating CF/Net income |
2.67 | 1.41 | 0.38 | 0.47 | |
Depreciation/Fixed assets |
0.20 | 0.18 | 0.18 | 0.21 | |
Capex/Depreciation |
(1.80) | (1.86) | (1.95) | (1.95) | |
Revenue per Share |
4.20 | 4.03 | 3.95 | 3.97 | |
Operating CF per Share |
1.07 | 0.64 | 0.23 | 0.12 | |
Capex per Share |
(0.32) | (0.32) | (0.32) | (0.33) | |
Capex to Sales |
0.08 | 0.08 | 0.08 | 0.08 |
Columns are period end dates · fundamentals updated 28 Sep 2026